Implantable Cardioverter-Defibrillator Performance and Therapy Optimization

Implantable cardioverter-defibrillators (ICDs) have transformed the management of patients at risk of sudden cardiac death by combining continuous rhythm monitoring with therapies that interrupt life-threatening arrhythmias. Optimizing device performance requires a delicate balance between ensuring rapid, reliable termination of ventricular tachycardia (VT) or ventricular fibrillation (VF) and minimising unnecessary interventions that can cause myocardial injury, accelerate battery depletion and diminish patient quality of life. Advances in programming algorithms, sensing modalities and biomarker discovery have enabled more individualised detection thresholds, extended detection intervals and intelligent discrimination of true arrhythmias from artefact. Proteomic analyses and novel electrophysiological sensors offer new insights into tissue responses to shock delivery, driving efforts to refine shock energy, minimise myocardial damage and improve long-term outcomes. A global consensus on ICD therapy optimisation emphasises shared decision-making, evidence-based programming and vigilance for device-related complications.

Research from Nature Portfolio

Recent studies have applied quantitative proteomics in an ovine model to characterise acute myocardial alterations immediately following high-energy ICD shocks. Analysis of right-ventricular tissue both adjacent to and remote from the shock site revealed widespread protein, DNA and membrane damage, metabolic remodelling, oxidative stress, calcium dysregulation, inflammation and early fibrotic signalling. A decrease in N-terminally acetylated troponin C emerged as a potential tissue biomarker of shock-induced injury. These findings illuminate the paradox of life-saving defibrillation that nonetheless provokes cellular stress and suggest opportunities for tailored shock protocols, pharmacological mitigation of injury pathways and improved lead design to attenuate deleterious tissue responses.

Implantable Cardioverter-Defibrillator Performance and Therapy Optimization publication trend

The graph below shows the total number of articles in implantable cardioverter-defibrillator performance and therapy optimization across all publications each year (not limited to Nature Index journals).

Technical terms

Implantable cardioverter-defibrillator (ICD): An implanted device that continuously monitors heart rhythm and delivers therapies—either pacing or shocks—to terminate dangerous ventricular arrhythmias.

Antitachycardia pacing (ATP): A therapy in which rapid pacing stimuli are delivered to interrupt and terminate ventricular tachycardia without requiring a high-energy shock.

Ventricular tachycardia (VT): A fast but organised rhythm originating in the ventricles that may degrade into ventricular fibrillation if left untreated.

Ventricular fibrillation (VF): A chaotic ventricular rhythm with no effective contraction, leading to immediate cessation of cardiac output and necessitating prompt defibrillation.

Proteomics: The large-scale study of proteins, their modifications and interactions, used here to identify molecular changes in myocardial tissue following electrical shocks.

Defibrillation threshold (DFT): The minimum energy output at which an ICD shock reliably terminates ventricular fibrillation in a given patient under test conditions.

References

1. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm (2019).
2. Quantification of Electromechanical Coupling to Prevent Inappropriate Implantable Cardioverter-Defibrillator Shocks. JACC Clinical Electrophysiology (2019).
3. Acute pathophysiological myocardial changes following intra-cardiac electrical shocks using a proteomic approach in a sheep model. Scientific Reports (2020).
4. Antitachycardia pacing success in implantable cardioverter-defibrillators by patient, device, and programming characteristics. Heart Rhythm (2022).